CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Call for Patient Input: Inflectra

Published on: March 11, 2016
Result type: News

CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website.


Brand name Generic name Manufacturer Indication(s)

Inflectra (Subsequent Entry Biologic)

Infliximab Hospira HealthCare Corporation, a Pfizer Company Crohn’s disease and Ulcerative Colitis
Project Number Call for patient input Patient input deadline Submit patient input
TBC 2016-03-11 2016-05-02 Submit